Ponesimod
RxNorm 2532300
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 2532300 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: ponesimod.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
INPrescribable
Ingredient (IN):
Ponesimod
(Atom ID: 12618125)
PTPrescribable
Designated preferred name (PT):
Ponesimod
(Atom ID: 12726499)
FNPrescribable
Full form of descriptor (FN):
Ponesimod (substance)
(Atom ID: 12726500)
PTPrescribable
Designated preferred name (PT):
Ponesimod-containing product
(Atom ID: 12726512)
FNPrescribable
Full form of descriptor (FN):
Product containing ponesimod (medicinal product)
(Atom ID: 12727003)
Patient Education
Ponesimod
Ponesimod is used to prevent episodes of symptoms and slow the worsening of disability in adults who have relapsing forms of multiple sclerosis (MS; a disease in which the nerves do not function properly and people may experience weakness, numbness, loss of muscle coordination, and problems with vision, speech, and bladder control), including: clinically isolated syndrome (CIS; first nerve symptom episode that lasts at least 24 hours), relapsing-remitting disease (course of disease where symptoms flare up from time to time), active secondary progressive disease (later stage of disease with continuous worsening of symptoms.) Ponesimod is in a class of medications called sphingosine l-phosphate receptor modulators. It works by decreasing the action of immune cells that may cause nerve damage.
[Learn More]
* Please review the disclaimer below.
